Histo-Blood Group Antigens in Children with Symptomatic Rotavirus Infection.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
10 04 2019
Historique:
received: 18 02 2019
revised: 26 03 2019
accepted: 09 04 2019
entrez: 13 4 2019
pubmed: 13 4 2019
medline: 30 4 2020
Statut: epublish

Résumé

Group A rotaviruses are a major cause of acute gastroenteritis in children. The diversity and unequal geographical prevalence of rotavirus genotypes have been linked to histo-blood group antigens (HBGAs) in different human populations. In order to evaluate the role of HBGAs in rotavirus infections in our population, secretor status (FUT2+), ABO blood group, and Lewis antigens were determined in children attended for rotavirus gastroenteritis in Valencia, Spain. During three consecutive years (2013-2015), stool and saliva samples were collected from 133 children with rotavirus infection. Infecting viral genotypes and HBGAs were determined in patients and compared to a control group and data from blood donors. Rotavirus G9P[8] was the most prevalent strain (49.6%), followed by G1P[8] (20.3%) and G12P[8] (14.3%). Rotavirus infected predominantly secretor (99%) and Lewis b positive (91.7%) children. Children with blood group A and AB were significantly more prone to rotavirus gastroenteritis than those with blood group O. Our results confirm that a HBGA genetic background is linked to rotavirus P[8] susceptibility. Rotavirus P[8] symptomatic infection is manifestly more frequent in secretor-positive (FUT2+) than in non-secretor individuals, although no differences between rotavirus G genotypes were found.

Identifiants

pubmed: 30974776
pii: v11040339
doi: 10.3390/v11040339
pmc: PMC6520971
pii:
doi:

Substances chimiques

Blood Group Antigens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Nature. 2012 Apr 15;485(7397):256-9
pubmed: 22504179
Gastroenterology. 2002 Jun;122(7):1967-77
pubmed: 12055602
Biologicals. 2010 Jan;38(1):170-7
pubmed: 20093043
Sci Rep. 2016 Oct 06;6:34591
pubmed: 27708367
Expert Rev Mol Med. 2014 Mar 10;16:e5
pubmed: 24606759
Sci Rep. 2018 Jan 24;8(1):1502
pubmed: 29367698
Sci Rep. 2017 Mar 30;7:45559
pubmed: 28358023
Cell Host Microbe. 2018 Aug 8;24(2):197-207.e4
pubmed: 30092197
Adv Exp Med Biol. 2004;554:135-43
pubmed: 15384573
Sci Rep. 2018 Aug 28;8(1):12961
pubmed: 30154494
JAMA Pediatr. 2015 Nov;169(11):1040-5
pubmed: 26389824
Biochem J. 2004 Nov 1;383(Pt. 3):469-74
pubmed: 15250822
J Infect Dis. 2010 Sep 1;202 Suppl:S34-42
pubmed: 20684715
Biochimie. 2001 Jul;83(7):565-73
pubmed: 11522384
Clin Infect Dis. 2014 Dec 1;59(11):1567-73
pubmed: 25097083
PLoS One. 2013 Nov 11;8(11):e78113
pubmed: 24244290
Biol Neonate. 2001 Feb;79(2):91-6
pubmed: 11223649
Nat Commun. 2018 Jul 6;9(1):2631
pubmed: 29980685
N Engl J Med. 2010 Jan 28;362(4):289-98
pubmed: 20107214
Nat Med. 2003 May;9(5):548-53
pubmed: 12692541
Emerg Infect Dis. 2015 Nov;21(11):2055-8
pubmed: 26488868
J Clin Microbiol. 2014 May;52(5):1366-74
pubmed: 24523471
Rev Med Virol. 2005 Jan-Feb;15(1):29-56
pubmed: 15484186
J Virol. 2012 May;86(9):4833-43
pubmed: 22345472
Emerg Infect Dis. 2012 Apr;18(4):589-97
pubmed: 22469076
PLoS One. 2013 Jul 19;8(7):e69557
pubmed: 23894502
Pediatr Neonatol. 2012 Feb;53(1):18-23
pubmed: 22348490
Nat Commun. 2015 Jan 05;6:5907
pubmed: 25556995
BMC Infect Dis. 2019 Nov 27;19(1):998
pubmed: 31771522
J Infect Dis. 2010 Sep 1;202 Suppl:S23-33
pubmed: 20684708
PLoS One. 2009;4(5):e5593
pubmed: 19440360
Emerg Microbes Infect. 2017 Apr 12;6(4):e22
pubmed: 28400594
Lancet. 2010 Aug 21;376(9741):606-14
pubmed: 20692030
Epidemiol Infect. 2011 Jun;139(6):895-909
pubmed: 20707941
Glycoconj J. 1997 Feb;14(2):209-23
pubmed: 9111138
Lancet Infect Dis. 2012 Feb;12(2):136-41
pubmed: 22030330
J Virol. 2016 Oct 14;90(21):9983-9996
pubmed: 27558427
J Med Virol. 2004 Jan;72(1):156-61
pubmed: 14635025
J Infect Dis. 2014 Apr 15;209(8):1227-30
pubmed: 24277741
J Infect Dis. 2002 May 1;185(9):1335-7
pubmed: 12001052
J Infect Dis. 2017 Jan 1;215(1):34-41
pubmed: 27803175

Auteurs

Raúl Pérez-Ortín (R)

Department of Microbiology, School of Medicine, University of Valencia and Clinical Microbiology Service, Hospital Clínico Universitario de Valencia, Instituto de Investigación INCLIVA, 46010 Valencia, Spain. raul.perez@clinicalapau.es.

Susana Vila-Vicent (S)

Department of Microbiology, School of Medicine, University of Valencia and Clinical Microbiology Service, Hospital Clínico Universitario de Valencia, Instituto de Investigación INCLIVA, 46010 Valencia, Spain. susana.vila@uv.es.

Noelia Carmona-Vicente (N)

Department of Microbiology, School of Medicine, University of Valencia and Clinical Microbiology Service, Hospital Clínico Universitario de Valencia, Instituto de Investigación INCLIVA, 46010 Valencia, Spain. noelia.carmona@uv.es.

Cristina Santiso-Bellón (C)

Department of Microbiology, School of Medicine, University of Valencia and Clinical Microbiology Service, Hospital Clínico Universitario de Valencia, Instituto de Investigación INCLIVA, 46010 Valencia, Spain. cristina.santiso@hotmail.com.

Jesús Rodríguez-Díaz (J)

Department of Microbiology, School of Medicine, University of Valencia and Clinical Microbiology Service, Hospital Clínico Universitario de Valencia, Instituto de Investigación INCLIVA, 46010 Valencia, Spain. jesus.rodriguez@uv.es.

Javier Buesa (J)

Department of Microbiology, School of Medicine, University of Valencia and Clinical Microbiology Service, Hospital Clínico Universitario de Valencia, Instituto de Investigación INCLIVA, 46010 Valencia, Spain. javier.buesa@uv.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH